Skip to main content
HEALIOS K.K. logo

HEALIOS K.K. — Investor Relations & Filings

Ticker · 4593 ISIN · JP3835100003 LEI · 3538005FFIDTDLUZOE53 T Professional, scientific and technical activities
Open in API
Filings indexed 74 across all filing types
Latest filing 2019-03-28 Annual Report
Country JP Japan
Listing T 4593

About HEALIOS K.K.

https://www.healios.co.jp/en/

Healios K.K. is a clinical-stage biotechnology company specializing in the research and development of regenerative medicine and cell-based therapies. The company's pipeline is focused on addressing unmet medical needs in multiple therapeutic areas. Its lead programs include an allogeneic stem cell product in late-stage clinical development for ischemic stroke and Acute Respiratory Distress Syndrome (ARDS). Healios also leverages its proprietary induced pluripotent stem cell (iPSC) platform to develop next-generation treatments. This platform includes retinal pigment epithelium (RPE) cells for age-related macular degeneration and engineered natural killer (eNK) cells designed to target solid tumors. A key area of its research is the creation of Universal Donor Cells (UDCs) to produce hypoimmunogenic therapies.

Recent filings

Filing Released Lang Actions
有価証券報告書－第8期(平成30年1月1日－平成30年12月31日)
Annual Report Classification · 100% confidence The document is a 'Yuka Shoken Hokokusho' (Securities Report), which is the Japanese equivalent of a 10-K. It contains comprehensive financial statements, business descriptions, risk factors, and management analysis for the fiscal year ending December 31, 2018. It is a formal, long-form regulatory filing submitted to the Kanto Local Finance Bureau, not an announcement or a summary. FY 2018
2019-03-28 Japanese
四半期報告書－第8期第3四半期(2018/07/01－2018/09/30)
Interim / Quarterly Report Classification · 100% confidence The document is a 'Quarterly Report' (四半期報告書) for the third quarter of the fiscal year 2018, filed by HEALIOS K.K. with the Kanto Local Finance Bureau. It contains detailed financial statements, management analysis, and business updates, which aligns with the definition of an Interim/Quarterly Report (IR). 9M 2018
2018-11-08 Japanese
四半期報告書－第8期第2四半期(2018/04/01－2018/06/30)
Interim / Quarterly Report Classification · 100% confidence The document is a 'Quarterly Report' (四半期報告書) filed by HEALIOS K.K. in accordance with the Financial Instruments and Exchange Act of Japan. It contains detailed financial statements, management analysis (MD&A), and business updates for the second quarter of the fiscal year ending 2018. It is a comprehensive financial report for a period shorter than a full fiscal year, fitting the definition of an Interim/Quarterly Report (IR). H1 2018
2018-08-07 Japanese
四半期報告書－第8期第1四半期(2018/01/01－2018/03/31)
Interim / Quarterly Report Classification · 100% confidence The document is a 'Quarterly Report' (四半期報告書) for the company HEALIOS K.K. for the period from January 1, 2018, to March 31, 2018. It contains detailed financial statements (balance sheet, income statement), management analysis, and notes to the financial statements, which are required under the Financial Instruments and Exchange Act of Japan. This fits the definition of an Interim/Quarterly Report (IR). Q1 2018
2018-05-11 Japanese
有価証券報告書－第7期(平成29年1月1日－平成29年12月31日)
Annual Report Classification · 100% confidence The document is a '有価証券報告書' (Yuuka Shouken Houkokusho), which is the Japanese equivalent of a 10-K Annual Report. It contains detailed financial statements, business descriptions, risk factors, and corporate information for the fiscal year ending December 31, 2017. It is a comprehensive annual filing submitted to the Kanto Local Finance Bureau, not an announcement or a summary. FY 2017
2018-03-29 Japanese
四半期報告書－第7期第3四半期(2017/07/01－2017/09/30)
Interim / Quarterly Report Classification · 100% confidence The document is a 'Quarterly Report' (四半期報告書) for the third quarter of the fiscal year 2017, filed by HEALIOS K.K. with the Kanto Local Finance Bureau under the Financial Instruments and Exchange Act. It contains detailed financial statements (Balance Sheet, Income Statement), notes to financial statements, and management analysis for the period. As it is a comprehensive financial report for a period shorter than a full fiscal year containing substantive financial data, it is classified as an Interim/Quarterly Report (IR). 9M 2017
2017-11-08 Japanese

Browse filings by year

12 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.